Aldeyra Therapeutics Files 8-K
Ticker: ALDX · Form: 8-K · Filed: Jun 13, 2024 · CIK: 1341235
| Field | Detail |
|---|---|
| Company | Aldeyra Therapeutics, INC. (ALDX) |
| Form Type | 8-K |
| Filed Date | Jun 13, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, regulatory
Related Tickers: ALDX
TL;DR
Aldeyra filed a routine 8-K, no major news.
AI Summary
Aldeyra Therapeutics, Inc. filed an 8-K on June 13, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or new material events beyond the standard reporting requirements.
Why It Matters
This 8-K filing indicates Aldeyra Therapeutics is providing standard updates and financial information to the SEC, which is routine for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting purposes and does not disclose any new material risks or significant events.
Key Players & Entities
- Aldeyra Therapeutics, Inc. (company) — Registrant
- June 13, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Regulation FD Disclosure and Financial Statements and Exhibits.
What is the exact name of the company filing this report?
The exact name of the company is Aldeyra Therapeutics, Inc.
On what date was the earliest event reported in this filing?
The earliest event reported in this filing was on June 13, 2024.
In which state was Aldeyra Therapeutics, Inc. incorporated?
Aldeyra Therapeutics, Inc. was incorporated in Delaware.
What is the principal executive office address for Aldeyra Therapeutics, Inc.?
The principal executive office address is 131 Hartwell Avenue, Suite 320, Lexington, MA 02421.
Filing Stats: 535 words · 2 min read · ~2 pages · Grade level 9.9 · Accepted 2024-06-13 07:01:34
Key Financial Figures
- $0.001 — e on which registered Common Stock, $0.001 par value per share ALDX The Nasdaq
Filing Documents
- ea0207791-8k_aldeyra.htm (8-K) — 26KB
- ea020779101ex99-1_aldeyra.htm (EX-99.1) — 13KB
- 0001213900-24-052234.txt ( ) — 214KB
- aldx-20240613.xsd (EX-101.SCH) — 3KB
- aldx-20240613_lab.xml (EX-101.LAB) — 33KB
- aldx-20240613_pre.xml (EX-101.PRE) — 22KB
- ea0207791-8k_aldeyra_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALDEYRA THERAPEUTICS, INC. By: /s/ Todd C. Brady Name: Todd C. Brady, M.D., Ph.D. Title: Chief Executive Officer Dated June 13, 2024 2